Mackenzie Financial
AXSM icon

Mackenzie Financial’s Axsome Therapeutics AXSM Stock Holding History

Mackenzie Financial’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-3,382
Closed -$502K – 1458
2025
Q4 		$502K Hold
3,382
– – ﹤0.01% 1222
2025
Q3 		$411K Buy
3,382
+1,097
+48% +$124K ﹤0.01% 1297
2025
Q2 		$239K Sell
2,285
-54
-2% -$5.72K ﹤0.01% 1482
2025
Q1 		$273K Buy
+2,339
New +$266K ﹤0.01% 1413
2024
Q4 		– Sell
-2,339
Closed -$210K – 1701
2024
Q3 		$210K Buy
+2,339
New +$204K ﹤0.01% 1366

Other funds holding AXSM

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Mackenzie Financial's AXSM Position: Q1 2026 in Review

Mackenzie Financial sold out of Axsome Therapeutics (AXSM) in Q1 2026, closing a stake of 3,382 shares — an estimated $502K sold.

Mackenzie Financial first reported a position in AXSM in Q3 2024 and held it in 5 quarters. The position peaked at $502K in Q4 2025. 409 funds tracked by Wall St. Rank hold AXSM as of Q1 2026.

  • Mackenzie Financial reported no remaining Axsome Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Mackenzie Financial sold 3,382 Axsome Therapeutics shares in Q1 2026, an estimated $502K.
  • Mackenzie Financial first reported a position in Axsome Therapeutics in Q3 2024 and held it in 5 quarters.
  • Mackenzie Financial's Axsome Therapeutics position peaked at $502K in Q4 2025.
  • 409 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q1 2026.

Based on Mackenzie Financial's 13F filing for Q1 2026, filed 13 May 2026.